{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:21:59Z","timestamp":1783358519321,"version":"3.54.6"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["199498"],"award-info":[{"award-number":["199498"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation for Innovative New Diagnostics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The World Health Organization recommends changing the first-line antimicrobial treatment for gonorrhoea when\u2009\u2265\u20095% of <jats:italic>Neisseria gonorrhoeae<\/jats:italic> cases fail treatment or are resistant. Susceptibility to ceftriaxone, the last remaining treatment option has been decreasing in many countries. We used antimicrobial resistance surveillance data and developed mathematical models to project the time to reach the 5% threshold for resistance to first-line antimicrobials used for <jats:italic>N. gonorrhoeae<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales from 2000\u20132018 about minimum inhibitory concentrations (MIC) for ciprofloxacin, azithromycin, cefixime and ceftriaxone\u00a0and antimicrobial treatment in two groups, heterosexual men and women (HMW) and men who have sex with men (MSM). We developed two susceptible-infected-susceptible models to fit these data and produce projections of the proportion of resistance until 2030. The single-step model represents the situation in which a single mutation results in antimicrobial resistance. In the multi-step model, the sequential accumulation of resistance mutations is reflected by changes in the MIC distribution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The single-step model described resistance to ciprofloxacin well. Both single-step and multi-step models could describe azithromycin and cefixime resistance, with projected resistance levels higher with the multi-step than the single step model. For ceftriaxone, with very few observed cases of full resistance, the multi-step model was needed to describe long-term dynamics of resistance. Extrapolating from the observed upward drift in MIC values, the multi-step model projected\u2009\u2265\u20095% resistance to ceftriaxone could be reached by 2030, based on treatment pressure alone. Ceftriaxone resistance was projected to rise to 13.2% (95% credible interval [CrI]: 0.7\u201344.8%) among HMW and 19.6% (95%CrI: 2.6\u201354.4%) among MSM by 2030.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>New first-line antimicrobials for gonorrhoea treatment are needed. In the meantime, public health authorities should strengthen surveillance for AMR\u00a0in <jats:italic>N. gonorrhoeae<\/jats:italic> and implement strategies for continued antimicrobial stewardship. Our models show the utility of long-term representative surveillance of gonococcal antimicrobial susceptibility data and can be adapted for use in, and for comparison with, other countries.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08200-4","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:02:36Z","timestamp":1682010156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Projecting the development of antimicrobial resistance in Neisseria gonorrhoeae from antimicrobial surveillance data: a mathematical modelling study"],"prefix":"10.1186","volume":"23","author":[{"given":"Julien","family":"Riou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian L.","family":"Althaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonatan H.","family":"Grad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke C. M.","family":"Heijne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"8","key":"8200_CR1","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","volume":"17","author":"M Unemo","year":"2017","unstructured":"Unemo M, Bradshaw CS, Hocking JS, Vries HJC, Francis SC, Mabey D. Sexually transmitted infections: challenges ahead. Lancet Infect Diseases. 2017;17(8):e235-79.","journal-title":"Lancet Infect Diseases"},{"issue":"3","key":"8200_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1128\/CMR.00010-14","volume":"27","author":"M Unemo","year":"2014","unstructured":"Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587\u2013613.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"8200_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/sextrans-2012-050674","volume":"88","author":"F Ndowa","year":"2012","unstructured":"Ndowa F, Lusti-Narasimhan M, Unemo M. The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sex Transm Infect. 2012;88(5):317\u20138.","journal-title":"Sex Transm Infect"},{"key":"8200_CR4","unstructured":"WHO, \u2018Global progress report on HIV, viral hepatitis and sexually transmitted infections\u2019. 2021. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240027077. Accessed 29 Jun 2022"},{"issue":"6","key":"8200_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0022-5347(17)56978-5","volume":"121","author":"RE Berger","year":"1979","unstructured":"Berger RE, Alexander ER, Harnisch JP, Paulsen CA, Monda GD, Ansell J. Etiology, manifestations and therapy of acute epididymitis: prospective study of 50 cases. J Urol. 1979;121(6):750\u20134.","journal-title":"J Urol"},{"issue":"9","key":"8200_CR6","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/cid\/ciz145","volume":"69","author":"J Reekie","year":"2019","unstructured":"Reekie J, Donovan B, Guy R, Hocking JS, Kaldor JM, Mak D. Risk of Ectopic Pregnancy and Tubal Infertility Following Gonorrhea and Chlamydia Infections. Clin Infect Diseases\u202f: an official publication of the Infectious Diseases Society of America. 2019;69(9):1621\u20133.","journal-title":"Clin Infect Diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"7","key":"8200_CR7","doi-asserted-by":"publisher","first-page":"e1002344","DOI":"10.1371\/journal.pmed.1002344","volume":"14","author":"T Wi","year":"2017","unstructured":"Wi T, Lahra MM, Ndowa F, Bala M, Dillon JA Jr, Ramon-Pardo P. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collab-orative action. PLoS Med. 2017;14(7):e1002344.","journal-title":"PLoS Med"},{"key":"8200_CR8","doi-asserted-by":"crossref","unstructured":"Unemo M, Lahra MM, Escher M, Eremin S, Cole MJ, Galarza P, et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study. The Lancet Microbe.\u00a02021;2(11):e627\u201336.","DOI":"10.1016\/S2666-5247(21)00171-3"},{"issue":"1","key":"8200_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0956462419886775","volume":"31","author":"H Fifer","year":"2020","unstructured":"Fifer H, Saunders J, Soni S, Sadiq ST, FitzGerald M. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. Int J STD AIDS. 2020;31(1):4\u201315.","journal-title":"Int J STD AIDS"},{"issue":"10","key":"8200_CR10","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/jac\/dkq289","volume":"65","author":"SA Chisholm","year":"2010","unstructured":"Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65(10):2141\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"8200_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/QCO.0b013e328320a836","volume":"22","author":"JW Tapsall","year":"2009","unstructured":"Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opinion Infect Diseases. 2009;22(1):87\u201391.","journal-title":"Curr Opinion Infect Diseases"},{"issue":"9","key":"8200_CR12","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1128\/AAC.00304-09","volume":"53","author":"S Zhao","year":"2009","unstructured":"Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas RA. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009;53(9):3744\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"27","key":"8200_CR13","doi-asserted-by":"publisher","first-page":"1800323","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","volume":"23","author":"DW Eyre","year":"2018","unstructured":"Eyre DW, Sanderson ND, Lord E, Regisford-Reimmer N, Chau K, Barker L. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill. 2018;23(27):1800323.","journal-title":"Euro Surveill"},{"issue":"5","key":"8200_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1071\/SH19023","volume":"16","author":"M Unemo","year":"2019","unstructured":"Unemo M, et al. World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sexual health. 2019;16(5):412\u201325.","journal-title":"Sexual health"},{"key":"8200_CR15","doi-asserted-by":"crossref","unstructured":"Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S, et al. Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Euro Surveill.\u00a02022;27(24):2200455.","DOI":"10.2807\/1560-7917.ES.2022.27.24.2200455"},{"key":"8200_CR16","unstructured":"UK Health Security Agency. \u2018Gonococcal resistance to antimicrobials surveillance programme report\u2019. Available:\u00a0https:\/\/www.gov.uk\/government\/publications\/gonococcal-resistance-to-antimicrobials-surveillance-programme-grasp-report. Accessed 29 June\u00a02022."},{"issue":"5","key":"8200_CR17","doi-asserted-by":"publisher","first-page":"e1005611","DOI":"10.1371\/journal.ppat.1005611","volume":"12","author":"SM Fingerhuth","year":"2016","unstructured":"Fingerhuth SM, Bonhoeffer S, Low N, Althaus CL. Antibiotic-Resistant Neisseria gonorrhoeae spread faster with more treatment, not more sexual partners. PLOS Pathogens. 2016;12(5):e1005611. https:\/\/doi.org\/10.1371\/journal.ppat.1005611.","journal-title":"PLOS Pathogens"},{"issue":"6","key":"8200_CR18","doi-asserted-by":"publisher","first-page":"e042893","DOI":"10.1136\/bmjopen-2020-042893","volume":"11","author":"L Findlater","year":"2021","unstructured":"Findlater L, Mohammed H, Gobin M, Fifer H, Ross J, Geffen O. Developing a model to predict individualised treatment for gonorrhoea: a modelling study. BMJ Open. 2021;11(6):e042893.","journal-title":"BMJ Open"},{"issue":"10","key":"8200_CR19","doi-asserted-by":"publisher","first-page":"e1002416","DOI":"10.1371\/journal.pmed.1002416","volume":"14","author":"LK Whittles","year":"2017","unstructured":"Whittles LK, White PJ, Didelot X. Estimating the fitness cost and benefit of cefixime resistance in Neisseria gonorrhoeae to inform pre-scription policy: A modelling study. PLoS medicine. 2017;14(10):e1002416.","journal-title":"PLoS medicine"},{"key":"8200_CR20","doi-asserted-by":"publisher","first-page":"e8913","DOI":"10.7717\/peerj.8913","volume":"8","author":"D Cadosch","year":"2020","unstructured":"Cadosch D, Garcia V, Jensen JS, Low N, Althaus CL. Understanding the spread of de novo and transmitted macrolide-resistance in Mycoplasma genitalium. PeerJ. 2020;8:e8913.","journal-title":"PeerJ"},{"issue":"3","key":"8200_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/antibiotics7030060","volume":"7","author":"LK Whittles","year":"2018","unstructured":"Whittles LK, White PJ, Paul J, Didelot X. Epidemiological trends of antibiotic resistant Gonorrhoea in the United Kingdom. Antibiotics. 2018;7(3):60.","journal-title":"Antibiotics"},{"key":"8200_CR22","unstructured":"UK Health Security Agency.\u00a0\u2018Guidance GRASP protocol\u2019.\u00a02020. Available:\u00a0https:\/\/www.gov.uk\/government\/publications\/gonococcal-resistance-to-antimicrobials-surveillance-programme-grasp-protocol\/gonococcal-resistance-to-antimicrobials-surveillance-programme-grasp-protocol. Accessed 5 Apr\u00a02023."},{"key":"8200_CR23","unstructured":"EUCAST.\u00a0\u2018Clinical breakpoints and dosing of antibiotics\u2019. Available: https:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 29 June\u00a02022."},{"issue":"1","key":"8200_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v076.i01","volume":"76","author":"B Carpenter","year":"2017","unstructured":"Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: a probabilistic programming language. J Stat Softw. 2017;76(1):1\u201332.","journal-title":"J Stat Softw"},{"key":"8200_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jgar.2018.11.011","volume":"17","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Furuya R, Kobayashi I, Kanesaka I, Ohno A, Katsuse AK. Antimicrobial resistance and molecular characterisation of Neisseria gonorrhoeae isolates in Fukuoka, Japan, 1996\u20132016. J Global Antimic Resistance. 2019;17:3\u20137.","journal-title":"J Global Antimic Resistance"},{"key":"8200_CR26","doi-asserted-by":"crossref","unstructured":"Leach AJ, Morris PS, Smith-Vaughan H, Mathews JD. In vivo penicillin MIC drift to extremely high resistance in serotype 14 Streptococcus pneumoniae persistently colonizing the nasopharynx of an infant with chronic suppurative lung disease: a case study. Antimicro Agents Chemother. 2002;46(11):3648\u20139.","DOI":"10.1128\/AAC.46.11.3648-3649.2002"},{"issue":"1","key":"8200_CR27","doi-asserted-by":"publisher","first-page":"1-1","DOI":"10.1186\/s12879-015-1110-x","volume":"15","author":"K Shimuta","year":"2015","unstructured":"Shimuta K, Watanabe Y, S-i N, Morita-Ishihara T, Kuroki T, Unemo M. Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan. BMC Infect Dis. 2015;15(1):1\u20131.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"8200_CR28","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1128\/AAC.05760-11","volume":"56","author":"M Unemo","year":"2012","unstructured":"Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273\u201380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"8200_CR29","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1093\/jac\/dkr332","volume":"66","author":"SA Chisholm","year":"2011","unstructured":"Chisholm SA, Alexander S, Desouza-Thomas L, Maclure-Webster E, Anderson J, Nichols T. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother. 2011;66(11):2509\u201312.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"8200_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1473-3099(13)70693-5","volume":"14","author":"YH Grad","year":"2014","unstructured":"Grad YH, Kirkcaldy RD, Trees D, Dordel J, Harris SR, Goldstein E, et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study. Lancet Infect Dis. 2014;14(3):220\u20136.","journal-title":"Lancet Infect Dis"},{"key":"8200_CR31","doi-asserted-by":"crossref","unstructured":"Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, et al. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill.\u00a02013;18(3).","DOI":"10.2807\/ese.18.03.20358-en"},{"issue":"9","key":"8200_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41585-019-0206-2","volume":"16","author":"HV Dong","year":"2019","unstructured":"Dong HV, Klausner JD. Neisseria gonorrhoeae resistance driven by antibiotic use. Nat Rev Urol. 2019;16(9):509\u201310.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"8200_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/cid\/ciaa591","volume":"73","author":"M Marks","year":"2021","unstructured":"Marks M, Harding-Esch E. Antimicrobial Resistance in Gonorrhea: Diagnostics to the Rescue. Clin Infect Dis. 2021;73(2):304\u20135.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"8200_CR34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S1473-3099(21)00625-3","volume":"22","author":"HJ de Vries","year":"2022","unstructured":"de Vries HJ, de Laat M, Jongen VW, Heijman T, Wind CM, Boyd A, et al. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis. 2022;22(5):706\u201317.","journal-title":"Lancet Infect Dis"},{"key":"8200_CR35","unstructured":"Global Antibiotics Research and Development Partnership, \u2018Zoliflodacin in Uncomplicated Gonorrhoea\u2019. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03959527"},{"issue":"28","key":"8200_CR36","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1016\/j.vaccine.2020.02.073","volume":"38","author":"SL Gottlieb","year":"2020","unstructured":"Gottlieb SL, Ndowa F, Hook EW III, Deal C, Bachmann L, Abu-Raddad L, et al. Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine. 2020;38(28):4362\u201373.","journal-title":"Vaccine"},{"issue":"1","key":"8200_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-017-0881-x","volume":"15","author":"SM Fingerhuth","year":"2017","unstructured":"Fingerhuth SM, Low N, Bonhoeffer S, Althaus CL. Detection of antibiotic resistance is essential for gonorrhoea point-of-care testing: a mathematical modelling study. BMC Medicine. 2017;15(1):1\u20132.","journal-title":"BMC Medicine"},{"key":"8200_CR38","doi-asserted-by":"crossref","unstructured":"Cole MJ, Day M, Jacobsson S, Amato-Gauci AJ, Spiteri G, Unemo M. The European response to control and manage multi-and extensively drug-resistant Neisseria gonorrhoeae. Euro Surveill. 2022;27(18):2100611.","DOI":"10.2807\/1560-7917.ES.2022.27.18.2100611"},{"key":"8200_CR39","doi-asserted-by":"crossref","unstructured":"Hofstraat SH, G\u00f6tz HM, van Dam AP, van der Sande MA, van Benthem BH. Trends and determinants of antimicrobial susceptibility of Neisseria gonorrhoeae in the Netherlands, 2007 to 2015. Euro Surveill. 2018;23(36):1700565.","DOI":"10.2807\/1560-7917.ES.2018.23.36.1700565"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08200-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:03:35Z","timestamp":1682010215000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08200-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8200"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08200-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"22 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific consent is required from participants because GRASP is routine public health surveillance and UK Health Security Agency has permission to handle data obtained by under Sect.\u00a0251 of the UK National Health Service Act of 2006, which was renewed annually by the ethics and confidentiality committee of the National Information Governance Board until 2013. Since 2013, UK Health Security Agency has had the power of approval of public health surveillance activity under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002. Anonymised data was used for this specific study. All methods were carried out in accordance with relevant guidelines and regulations. The original statement was used in a recent study using the same data ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NL is a member of the advisory board of Sefunda AG, a diagnostics company, which develops rapid tests for sexually transmitted infections, including detection of antimicrobial resistance. All the other authors do not possess any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}